Abstract:Alzheimer's disease accounts for 60-70% of dementia cases. Current treatments are inadequate and there is a need to develop new approaches to drug discovery. Recently, in cancer, morphological profiling has been used in combination with high-throughput screening of small-molecule libraries in human cells in vitro. To test feasibility of this approach for Alzheimer's disease, we developed a cell morphology-based drug screen centred on the risk gene, SORL1 (which encodes the protein SORLA). Increased Alzheimer's disease risk has been repeatedly linked to variants in SORL1, particularly those conferring loss or decreased expression of SORLA, and lower SORL1 levels are observed in post-mortem brain samples from individuals with Alzheimer's disease. Consistent with its role in the endolysosomal pathway, SORL1 deletion is associated with enlarged endosomes in neural progenitor cells and neurons. We, therefore, hypothesized that multi-parametric, image-based cell phenotyping would identify features characteristic of SORL1 deletion. An automated morphological profiling method (Cell Painting) was adapted to neural progenitor cells and used to determine the phenotypic response of SORL1-/- neural progenitor cells to treatment with compounds from a small internationally approved drug library (TargetMol, 330 compounds). We detected distinct phenotypic signatures for SORL1-/- neural progenitor cells compared to isogenic wild-type controls. Furthermore, we identified 16 compounds (representing 14 drugs) that reversed the mutant morphological signatures in neural progenitor cells derived from three SORL1-/- induced pluripotent stem cell sub-clones. Network pharmacology analysis revealed the 16 compounds belonged to five mechanistic groups: 20S proteasome, aldehyde dehydrogenase, topoisomerase I and II, and DNA synthesis inhibitors. Enrichment analysis identified DNA synthesis/damage/repair, proteases/proteasome and metabolism as key pathways/biological processes. Prediction of novel targets revealed enrichment in pathways associated with neural cell function and Alzheimer's disease. Overall, this work suggests that (i) a quantitative phenotypic metric can distinguish induced pluripotent stem cell-derived SORL1-/- neural progenitor cells from isogenic wild-type controls and (ii) phenotypic screening combined with multi-parametric high-content image analysis is a viable option for drug repurposing and discovery in this human neural cell model of Alzheimer's disease.

Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine

The 37TrillionCells initiative for improving global healthcare via cell-based interception and precision medicine: focus on neurodegenerative diseases

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

LifeTime and Improving European Healthcare Through Cell-Based Interceptive Medicine.

Cell Replacement Therapy Improves Pathological Hallmarks in a Mouse Model of Leukodystrophy Vanishing White Matter

Toward Precision Medicine in Neurological Diseases.

Profiling drug sensitivity of leukemic stem cells via bulk-to-single-cell deconvolution

Novel precision medicine approaches and treatment strategies in hematological malignancies

TARGETED DRUG DELIVERY OF LEUKOMIMETIC NANOPARTICLES TO ALLEVIATE PERIPHERAL NEUROPATHY IN CHARCOT-MARIE-TOOTH 1X

Biomarker-Based Precision Therapy for Alzheimer's Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine

Cnsc-58. Bioprocessing Of Viable Surgical Pediatric Brain Tumor Specimens For Genome-Guided Personalized Drug Testing

The Potential of Circulating Cell-Free DNA in Precision Neurology

Epco-36. Integrative Deep-Learning And Pharmacogenomic Profiling Of Malignant Gliomas Using Patient-Derived Tumor Cells

Precision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project

Morphological profiling in human neural progenitor cells classifies hits in a pilot drug screen for Alzheimer's disease

Deciphering Early and Progressive Molecular Signatures in Alzheimer's Disease through Integrated Longitudinal Proteomic and Pathway Analysis in a Rodent Model

Exth-16. Unbiased Discovery Of Synergistic Vulnerabilities Against Glioblastoma: An Innovativein Vivo Crispr Profiling Platform To Unleash The Power Of Tumor-Targeted Cytokine Therapy

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: our experience with Open Science in ALS

Personalized Prediction of Future Lesion Activity and Treatment Effect in Multiple Sclerosis from Baseline MRI

Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models